Skip to main content

This website is intended for US healthcare professionals only.

INGREZZA® (valbenazine) capsules

Neurocrine Access Support for INGREZZA

One goal: Access for every patient prescribed INGREZZA

Neurocrine Access Support

Neurocrine Access Support is a program created to assist you, your staff, and your patients by providing essential resources and information to help your patients start and stay on INGREZZA. Download and fax the INGREZZA Treatment form, which enrolls patients in the Neurocrine Access Support program and serves as their INGREZZA prescription through one of our national specialty pharmacies.

Call 1-84-INGREZZA (1-844-647-3992), 8 am to 8 pm ET, Monday through Friday, to learn more.

LEARN MORE TREATMENT FORM

~90% of patients pay $10 or less for INGREZZA.1

Financial assistance options are available to help your patients start and stay on treatment

Now it’s easier than ever for your patients to access INGREZZA

More than 80% of patients are approved for INGREZZA nationwide.2

~90% of patients pay $10 or less for INGREZZA.1

Financial assistance options are available to help your patients start and stay on treatment

Now it’s easier than ever for your patients to access INGREZZA

More than 80% of patients are approved for INGREZZA nationwide.2

Dedicated local experts provide personalized access solutions to you and your office staff

Our Regional Patient Access Managers (RPAMs) are available to help you and your office navigate access

Start your patients on INGREZZA right away

INGREZZA® (valbenazine) capsules packaging

INGREZZA SAMPLES

Request samples of INGREZZA today to start patients on treatment

REQUEST INFO

FREE TRIAL OFFER

Request a free one-month supply of INGREZZA for new patients

REQUEST TRIAL

The free trial is not contingent on a purchase of any kind. Product dispensed under this free trial program may not be submitted for reimbursement to any third-party payer. We reserve the right to modify or cancel the program at any time. Additional terms and conditions apply.

INGREZZA SAVINGS PROGRAM*

$0 cost for INGREZZA is possible for most eligible commercially insured patients through the Savings Program

*This offer is valid only for patients with commercial (nongovernment-funded) insurance. Additional terms and conditions apply.

DOWNLOAD COPAY CARD

INGREZZA PATIENT ASSISTANCE PROGRAM†

The INGREZZA patient assistance program is designed to provide support for patients who have no insurance, those with insurance but lacking prescription coverage for INGREZZA -or- who demonstrate a qualifying financial need. If eligible, your patient will receive their medications at no cost.

†Additional terms and conditions apply.

APPLY FOR ASSISTANCE

LOOKING FOR MORE ACCESS RESOURCES?

Download access-related forms and templates to help you and your practice

DOWNLOAD RESOURCES

REFERENCE:

  1. Data on file; 09/2024 through 02/2025. Neurocrine Biosciences, Inc.
  2. Data on file; 07/2025 Neurocrine Biosciences, Inc.
+Expand-Collapse

Important Safety Information

Depression and Suicidality in Patients with Huntington’s Disease: VMAT2 inhibitors, including INGREZZA, can increase the risk of depression and suicidal thoughts and

Important Information

INDICATION & USAGE

INGREZZA® (valbenazine) capsules and INGREZZA® SPRINKLE (valbenazine) capsules are indicated in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington’s disease.

IMPORTANT SAFETY INFORMATION

Depression and Suicidality in Patients with Huntington’s Disease: VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in patients with Huntington’s disease.